Cabazitaxel-d6

CAT: 0804-HY-15459SSize: 1 mgDry Ice: NoHazardous: No
CAT#:0804-HY-15459SSize:1 mg
Selected
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
Cabazitaxel-d6 is the deuterium labeled Cabazitaxel. Cabazitaxel is a semi-synthetic derivative of the natural taxoid 10-deacetylbaccatin III with potential antineoplastic activity[1][2].
CAS Number
[1383561-29-2]
Product Name Alternative
XRP6258-d6; RPR-116258A-d6; taxoid XRP6258-d6
UNSPSC
12352005
Hazard Statement
H302, H315, H341, H361, H373
Target
Autophagy; Microtubule/Tubulin
Type
Isotope-Labeled Compounds
Related Pathways
Autophagy; Cell Cycle/DNA Damage; Cytoskeleton
Field of Research
Cancer
Purity
97.90
Solubility
10 mM in DMSO|DMSO : ≥ 100mg/mL
Smiles
CC(O[C@]([C@@]1([H])C[C@@H]2OC([2H])([2H])[2H])(CO1)[C@@]([C@@]2(C([C@@H]3OC([2H])([2H])[2H])=O)C)([H])[C@@H]([C@@](C(C)(C3=C4C)C)(C[C@@H]4OC([C@H](O)[C@H](C5=CC=CC=C5)NC(OC(C)(C)C)=O)=O)O)OC(C6=CC=CC=C6)=O)=O
Molecular Formula
C45H51D6NO14
Molecular Weight
841.97
Precautions
H302, H315, H341, H361, H373
References & Citations
[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216. |[2]Gdowski AS, et al. Bone-targeted cabazitaxel nanoparticles for metastatic prostate cancer skeletal lesions and pain. Nanomedicine (Lond) . 2017 Sep;12 (17) :2083-2095.|[3]Tai X, et al. Cabazitaxel and indocyanine green co-delivery tumor-targeting nanoparticle for improved antitumor efficacy and minimized drug toxicity. J Drug Target. 2016 Sep 9:1-29.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C, 3 years (Powder)
Scientific Category
Isotope-Labeled Compounds
Clinical Information
No Development Reported

Popular Products